Src Continues Aging: Current and Future Clinical Directions
Open Access
- 15 December 2007
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (24), 7232-7236
- https://doi.org/10.1158/1078-0432.ccr-07-1902
Abstract
Aberrant activation of members of the Src family of nonreceptor protein tyrosine kinases is common in solid tumor malignancies and may contribute to the development and/or progression of these tumors. As a result, four Src inhibitors are now in more than 50 clinical trials for at least 14 different types of solid tumors. In this review, we briefly discuss the preclinical rationale for Src inhibitors, the development strategies most likely to be successful in the clinic, and the rationale for Src inhibitors in combination with other agents as part of a more comprehensive therapeutic strategy. As the use of Src family inhibitors in clinical trials on solid tumors is in its infancy, further studies on the roles of Src family kinases in tumor progression, chemoresistance, epidermal-to-mesenchymal transition, and other properties of tumor progression will be important in designing the most effective clinical trials using these inhibitors.Keywords
Other Versions
This publication has 49 references indexed in Scilit:
- Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cellsThe Journal of Steroid Biochemistry and Molecular Biology, 2007
- The role of Src in prostate cancerAnnals of Oncology, 2007
- Src, chemoresistance and epithelial to mesenchymal transition: are they related?Anti-Cancer Drugs, 2007
- Dasatinib Inhibits Migration and Invasion in Diverse Human Sarcoma Cell Lines and Induces Apoptosis in Bone Sarcoma Cells Dependent on Src Kinase for SurvivalCancer Research, 2007
- Overexpression of c-Src in areas of hyperproliferation in head and neck cancer, premalignant lesions and benign mucosal disordersJournal of Oral Pathology & Medicine, 2007
- Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transitionCurrent Opinion in Cell Biology, 2005
- Inhibition of Src Tyrosine Kinase as Treatment for Human Pancreatic Cancer Growing Orthotopically in Nude MiceClinical Cancer Research, 2004
- Expression of Kinase-defective Mutants of c-Src in Human Metastatic Colon Cancer Cells Decreases Bcl-xL and Increases Oxaliplatin- and Fas-induced ApoptosisPublished by Elsevier BV ,2004
- siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivityJournal of the American College of Surgeons, 2004
- Src kinase contributes to the metastatic spread of carcinoma cellsOncogene, 2002